VERAXA Biotech Begins Trading on NASDAQ Under Ticker VRXA After Business Combination

VERAXA Biotech (NASDAQ: VRXA) has begun trading on the NASDAQ Capital Market following the successful conclusion of a business combination with Voyager Acquisition Corp., as announced on June 11, 2026. The company is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific ADCs, and proprietary BiTAC-based therapeutic formats across multiple cancer indications.

VERAXA’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. This approach positions the company within two rapidly growing segments of the global oncology therapeutics market: ADCs and T-cell engagers (TCEs).

Through selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (RICs) and antibody-oligonucleotide conjugates (AOCs). The company’s vision is to deliver the next wave of smart cancer therapies with curative potential for solid tumors.

Investors should consider the forward-looking statements included in the original announcement, which are subject to risks and uncertainties as detailed in the company’s filings with the SEC. For more information, please refer to the full terms of use and disclaimers on the InvestorBrandNetwork website.